p53 gene therapy for hepatocellular carcinoma

References (10)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–917
2. Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011; 253: 453–69
3. Ueno K, Miyazono N, Inoue H, Nishida H, Kanetsuki I, Nakajo M. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 2000; 88: 1574–81
4. Sugioka A, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery 1993; 113: 612–8
5. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–2
6. Aravalli RN, Steer CJ, Cressman ENK. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047–63
7. Huang S, He X.The role of microRNAs in liver cancer progression. British Journal of Cancer 2011; 104: 235–40
8. Nault JC, Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin Liver Dis 2011; 31: 173-87
9. Hsia CC, Nakashima Y, Thorgeirsson SS, Harris CC, Minemura M, Momosaki S, Wang NJ, Tabor E. Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma. Oncol Rep 2000; 7: 353–6
10. Duan F, Lam MG. Delivery approaches of gene therapy in hepatocellular carcinoma. Anticancer Res 2013; 33: 4711-8.